1. Search Result
Search Result
Results for "

Cornea

" in MedChemExpress (MCE) Product Catalog:

10

Inhibitors & Agonists

5

Peptides

1

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P1222
    LL-37, human
    2 Publications Verification

    Bacterial Infection
    LL-37, human is a 37-residue, amphipathic, cathelicidin-derived antimicrobial peptide, which exhibits a broad spectrum of antimicrobial activity. LL-37, human could help protect the cornea from infection and modulates wound healing .
    LL-37, human
  • HY-P1222A
    LL-37, human TFA
    2 Publications Verification

    Bacterial Infection
    LL-37, human TFA is a 37-residue, amphipathic, cathelicidin-derived antimicrobial peptide, which exhibits a broad spectrum of antimicrobial activity. LL-37, human TFA could help protect the cornea from infection and modulates wound healing .
    LL-37, human TFA
  • HY-P1222B
    LL-37, human acetate
    2 Publications Verification

    Bacterial Infection Inflammation/Immunology
    LL-37, human acetate is a 37-residue, amphipathic, cathelicidin-derived antimicrobial peptide, which exhibits a broad spectrum of antimicrobial activity. LL-37, human acetate could help protect the cornea from infection and modulates wound healing .
    LL-37, human acetate
  • HY-B1323

    Dipivefrine hydrochloride

    Endogenous Metabolite Neurological Disease
    Dipivefrin hydrochloride (Dipivefrine hydrochloride) is an antiglaucoma proagent that is hydrolyzed to the active compound, epinephrine, by esterases in the cornea .
    Dipivefrin hydrochloride
  • HY-B1323S

    Dipivefrine-d6 hydrochloride

    Isotope-Labeled Compounds Endogenous Metabolite Neurological Disease
    Dipivefrin-d6 (hydrochloride) is deuterium labeled Dipivefrin (hydrochloride). Dipivefrin hydrochloride (Dipivefrine hydrochloride) is an antiglaucoma proagent that is hydrolyzed to the active compound, epinephrine, by esterases in the cornea[1][2].
    Dipivefrin-d6 hydrochloride
  • HY-B1288

    Benoxinate hydrochloride

    Oxybuprocaine hydrochloride (Benoxinate hydrochloride) reversibly blocks sodium channels and prevents propagation of painful nerve impulses in the cornea, conjunctiva, and sclera. Oxybuprocaine hydrochloride is used especially in ophthalmology and otolaryngology .
    Oxybuprocaine hydrochloride
  • HY-B0577
    Latanoprost
    1 Publications Verification

    PHXA41

    Prostaglandin Receptor Others
    Latanoprost (PHXA41) is a prostaglandin F2α analogue and can be used for glaucoma research. Latanoprost can effectively pass through cornea and be hydrolyzed by esterase to latanoprost acid. latanoprost acid is an F-prostaglandin (FP) receptor agonist, and can effectively reduce intraocular pressure (IOP) by increasing the outflow of aqueous humor through uvea .
    Latanoprost
  • HY-P1194

    Neurokinin Receptor Inflammation/Immunology
    Spantide I, a substance P analog, is a selective NK1 receptor antagonist, with Ki values of 230 nM and 8150 nM for NK1 and NK2 receptor, respectively. Spantide I provides an approach to reduce type 1 and enhance the type 2 cytokine IL-10 in the infected cornea, leading to a significant reduction in corneal perforation .
    Spantide I
  • HY-P1194A

    Neurokinin Receptor Inflammation/Immunology
    Spantide I TFA, a substance P analog, is a selective NK1 receptor antagonist, with Ki values of 230 nM and 8150 nM for NK1 and NK2 receptor, respectively. Spantide I provides an approach to reduce type 1 and enhance the type 2 cytokine IL-10 in the infected cornea, leading to a significant reduction in corneal perforation .
    Spantide I TFA
  • HY-155238

    GABA Receptor Neurological Disease
    E2730 is a noncompetitive but selective inhibitor of gamma-aminobutyric acid (GABA) transporter 1 (GAT1) with orally available and antiepileptic activity. E2730-mediated GAT1 inhibition is positively correlated with environmental GABA levels and selectively inhibits GAT1-mediated GABA uptake. E2730 (5-50 mg/kg; po) in rat amygdala ignition model, and in mouse cornea ignition (5-50 mg/kg), drug resistance 6Hz-44mA has demonstrated in vivo efficacy in models of psychomotor epilepsy (5-50 mg/kg), fragile X syndrome (2.5-300 mg/kg), and Dravet syndrome (10 mg/kg, 20 mg/kg) .
    E2730

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: